&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2026-03-09, 21:18

Menarini nears €4.9 billion in 2025 and focuses on talent and AI as ‘giant’ players enter pharma
Etsuko Liu

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2026-01-30, 20:00

Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
Bradley Crotty

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-03-31, 15:00

OPEN Health Appoints Matt D’Auria as Chief Executive Officer to Drive Innovation and Growth

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-02-16, 19:06

Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US
Jillian Pearce

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-06-11, 01:33

London Research & Pharmaceuticals (LRP) Presents the Advancement of LRP-661, Their Lead Drug Candidate, at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) Conference in Madrid, Spain, 5-8 May 2024

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-06-11, 01:33

London Research & Pharmaceuticals (LRP) Presents the Advancement of LRP-661, Their Lead Drug Candidate, at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) Conference in Madrid, Spain, 5-8 May 2024
Capemenoneise

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-04-09, 13:00

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma
Etsuko Liu

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-03-20, 00:58

CARBOGEN AMCIS announces successful ANVISA audit of its facility in China
Genie Cordner

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2023-03-16, 01:08

Hyloris reports full year results for 2022 & provides

Strong R&D progress & attractive commercial deals, including additional Tranexamic Acid RTU out-licensing dealsPotential U.S. market approval for...

Popular Posts